| Literature DB >> 35956391 |
Tsuyoshi Chiba1, Nanae Tanemura1.
Abstract
COVID-19 is still the biggest issue worldwide. Many dietary supplements on the market claim to have anti-COVID-19 effects without scientific evidence. To elucidate the prevalence of dietary supplement usage for the prevention of COVID-19, we conducted an online cross-sectional questionnaire survey among Japanese adults in January 2022. The prevalence of dietary supplement use for the prevention of COVID-19 was 8.3%, and there was no gender difference. We also conducted additional research on these dietary supplement users (1000 males and 1000 females). The most popular ingredient used was vitamin C (61.0%), with vitamin D (34.9%) and probiotics (33.4%) following. Half of these participants reported using supplements for more than one year. The information sources that reportedly led them to start using dietary supplements for the prevention of COVID-19 were the Internet (44.0%), television and radio (29.9%), and family or friends (26.0%), and these information sources differed among generations. In conclusion, some of the population used vitamin/mineral supplements for the prevention of COVID-19 that might be beneficial for their health, but some used ingredients with no scientifically proven effects against the virus at this time. Therefore, information-based scientific evidence is important to prevent the inappropriate use of dietary supplements by consumers.Entities:
Keywords: COVID-19; dietary supplements; information source
Mesh:
Substances:
Year: 2022 PMID: 35956391 PMCID: PMC9370294 DOI: 10.3390/nu14153215
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Characteristics of respondents.
|
| % | |
|---|---|---|
| Number | 48,925 | |
| Sex | ||
| Male | 25,739 | 52.6 |
| Female | 23,186 | 47.4 |
| Age | ||
| 20 s | 8320 | 17.0 |
| 30 s | 8437 | 17.2 |
| 40 s | 9461 | 19.3 |
| 50 s | 12,702 | 26.0 |
| Over 60 s | 10,005 | 20.4 |
| Areas of residence | ||
| Hokkaido | 2566 | 5.2 |
| Tohoku | 4336 | 8.9 |
| Kanto | 17,229 | 35.2 |
| Hokuriku | 1303 | 2.7 |
| Tokai | 6205 | 12.7 |
| Kinki | 7975 | 16.3 |
| Chugoku/Shikoku | 4510 | 9.2 |
| Kyushu/Okinawa | 4801 | 9.8 |
Experience of SARS-CoV-2 infection.
|
| % | |
|---|---|---|
| I have been diagnosed with COVID-19 | 775 | 1.9 |
| I have not been diagnosed with COVID-19 | 4345 | 10.8 |
| I have had symptoms, but did not visit a clinic | 822 | 2.0 |
| I have had no COVID-19 symptoms to date | 34,436 | 85.3 |
| People around 1 | ||
| Family members (live-in) | 928 | 2.3 |
| Family members (estranged) | 1133 | 2.8 |
| School friends or workplace colleagues | 4641 | 11.5 |
| Acquaintances | 3593 | 8.9 |
| Others | 1237 | 3.1 |
| No one | 30,323 | 75.1 |
1 Multiple answers.
The prevalence of dietary supplement usage for the prevention of SARS-CoV-2 infection.
|
| % | Male | Female | ||
|---|---|---|---|---|---|
| I currently use dietary supplements for the prevention of SARS-CoV-2 infection | 3362 | 8.3 | 8.4 | 8.2 | 0.541 |
| I do not use dietary supplements for the prevention of SARS-CoV-2 infection | 37,016 | 91.7 | 91.6 | 91.8 | |
| Reasons for not using ( | |||||
| I am not worried about SARS-CoV-2 infection | 4196 | 11.3 | 14.4 | 7.8 | <0.001 |
| I take adequate infection control measures (wearing masks, hand washing, gargling, avoiding 3C’s) | 15,137 | 40.9 | 41.9 | 39.8 | <0.001 |
| I do not think that dietary supplements can prevent coronavirus infection | 21,328 | 57.6 | 55.8 | 59.7 | <0.001 |
| I cannot afford to buy them | 7037 | 19.0 | 17.9 | 20.3 | <0.001 |
| I have seen “Information for Consumers Related to COVID-19” by the Consumer Affairs Agency | 486 | 1.3 | 1.5 | 1.1 | 0.006 |
| I have seen “Information for Consumers Related to COVID-19” by the NIBIOHN | 1091 | 2.9 | 3.1 | 2.8 | 0.106 |
| Others | 4196 | 11.3 | 14.4 | 7.8 | <0.001 |
CAA, Consumer Affairs Agency in Japan; NIBIOHN, National Institutes of Biomedical Innovation, Health and Nutrition. The difference among groups was examined using the chi-square (χ2) test. 1 Multiple answers.
The prevalence of dietary supplement usage for the prevention of SARS-CoV-2 infection according to the experience of SARS-CoV-2 infection.
|
| % | |
|---|---|---|
| I have been diagnosed with COVID-19 | 294 | 37.9 |
| I have not been diagnosed with COVID-19 | 617 | 14.2 |
| I have had symptoms, but did not visit a clinic | 173 | 21.0 |
| I have never had symptoms | 2273 | 6.6 |
| People around 1 | ||
| Family members (live-in) | 272 | 29.3 |
| Family members (estranged) | 205 | 18.1 |
| School friends or workplace colleagues | 552 | 11.9 |
| Acquaintances | 481 | 13.4 |
| Others | 108 | 8.7 |
| No one | 2062 | 6.8 |
1 Multiple answers. Each % was calculated as n divided by each n in Table 2.
The prevalence of dietary supplement usage other than for the prevention of SARS-CoV-2 infection.
|
| % | Male | Female | ||
|---|---|---|---|---|---|
| I currently use dietary supplement other than for the prevention of SARS-CoV-2 infection | 15,097 | 37.4 | 35.0 | 40.1 | <0.001 |
| I do not use dietary supplements other than for the prevention of SARS-CoV-2 infection | 25,281 | 62.6 | 65.0 | 59.9 |
The difference among groups was examined using the chi-square (χ2) test.
Factors associated with dietary supplement usage for the prevention of SARS-CoV-2 infection.
| Univariable | Multivariable | |||
|---|---|---|---|---|
| Sex | ||||
| Male | reference | reference | ||
| Female | 0.978 (0.911–1.050) | 0.541 | 0.733 (0.678–0.792) | <0.001 |
| Age | ||||
| 20 s | reference | reference | ||
| 30 s | 1.000 (0.893–1.120) | 0.993 | 0.881 (0.779–0.998) | 0.005 |
| 40 s | 0.887 (0.792–0.993) | 0.037 | 0.719 (0.636–0.812) | <0.001 |
| 50 s | 0.684 (0.612–0.763) | <0.001 | 0.493 (0.437–0.557) | <0.001 |
| Over 60 s | 0.713 (0.636–0.799) | <0.001 | 0.444 (0.392–0.503) | <0.001 |
| Cumulative number of newly confirmed SARS-CoV-2 infection per 100,000 population of residential prefecture 1 | ||||
| <15,000 | reference | reference | ||
| 15,001–30,000 | 1.100 (0.998–1.220) | 0.055 | 1.150 (1.030–1.270) | 0.001 |
| 30,000< 2 | 1.230 (1.120–1.340) | <0.001 | 1.200 (1.090–1.320) | <0.001 |
| Dietary supplement usage other than for the prevention of SARS-CoV-2 infection | ||||
| No | reference | reference | ||
| Yes | 20.60 (18.30–23.20) | <0.001 | 22.30 (19.80–25.10) | <0.001 |
1 Cumulative number from 16 Jun 2020 to 18 Jun 2022 (the day before the questionnaire). 2 Hyogo, Saitama, Chiba, Kanagawa, Osaka, Tokyo, and Okinawa in this segment.
Dietary supplements that the participants reported using for the prevention of SARS-CoV-2 infection.
|
| % | |
|---|---|---|
| Vitamin/Mineral | ||
| Vitamin C | 1199 | 61.0 |
| Vitamin D | 686 | 34.9 |
| Vitamin E | 614 | 31.2 |
| Zinc | 467 | 23.8 |
| Iron | 415 | 21.1 |
| Non-vitamin/non-mineral | ||
| Probiotics | 657 | 33.4 |
| Catechins | 367 | 18.7 |
| Echinacea | 56 | 2.8 |
| Cannabidiol (CBD) | 40 | 2.0 |
| Others | 253 | 12.9 |
Multiple answers.
Duration of dietary supplement use.
|
| % | |
|---|---|---|
| Within 1 week | 108 | 5.4 |
| 1 month | 198 | 9.9 |
| 2–3 months | 251 | 12.6 |
| 4–6 months | 255 | 12.8 |
| 7–11 months | 126 | 6.3 |
| More than 1 year | 1062 | 53.1 |
n = 2000.
Information sources that prompted the participants to use dietary supplements for the prevention of SARS-CoV-2 infection.
| All | 20 s | 30 s | 40 s | 50 s | 60 s | 70 s | ||
|---|---|---|---|---|---|---|---|---|
| Television or radio | 29.9 | 24.8 | 31.3 | 30.0 | 29.0 | 34.1 | 34.5 | 0.102 |
| Newspaper, magazine, or advertisement | 16.1 | 17.5 | 15.0 | 14.3 | 13.5 | 16.1 | 28.1 | 0.002 |
| Internet | 44.0 | 35.0 | 47.0 | 47.0 | 46.0 | 48.7 | 38.1 | <0.001 |
| SNS (LINE, Facebook, Twitter, Instagram) | 21.7 | 35.3 | 29.0 | 21.3 | 16.8 | 7.7 | 2.9 | <0.001 |
| Specialists (doctors, pharmacists, dieticians) | 9.6 | 13.5 | 12.3 | 6.0 | 9.0 | 7.3 | 7.2 | 0.002 |
| Store clerks in pharmacies or drugstores | 12.0 | 13.0 | 15.8 | 11.3 | 11.0 | 9.6 | 7.9 | 0.077 |
| Point-of-purchase adverts | 9.4 | 8.3 | 11.8 | 11.0 | 9.0 | 9.2 | 2.9 | 0.043 |
| Product packaging | 15.2 | 10.8 | 17.3 | 19.0 | 18.5 | 10.3 | 10.8 | <0.001 |
| Family, friends, or acquaintances | 26.0 | 25.0 | 27.0 | 22.3 | 27.5 | 26.8 | 30.2 | 0.394 |
| Others | 3.5 | 1.8 | 3.3 | 3.8 | 4.0 | 3.4 | 7.2 | 0.085 |
Multiple answers. The difference among minerals was examined using the chi-square (χ2) test.
The perception of “Information for Consumers Related to COVID-19” published by the NIBIOHN.
|
| % | |
|---|---|---|
| I know this site | 306 | 15.3 |
| I have seen this site | 351 | 17.6 |
| I have never seen this site | 1343 | 67.2 |
n = 2000.
The usefulness of “Information for Consumers Related to COVID-19” published by the NIBIOHN for users.
|
| % | |
|---|---|---|
| This site is very useful | 190 | 28.9 |
| This site is useful to some extent | 336 | 51.1 |
| This site is not very useful | 103 | 15.7 |
| This site is not useful at all | 23 | 3.5 |
| I know this site, but I have not seen the information on it | 5 | 0.8 |
n = 657 who answered “I know this site” and “I have seen this site” in Table 10.
The usefulness of “Information for Consumers Related to COVID-19” published by the NIBIOHN for non-users.
|
| % | |
|---|---|---|
| This site seems very useful | 211 | 15.7 |
| This site seems useful to some extent | 812 | 60.5 |
| This site seems not very useful | 241 | 17.9 |
| This site seems totally useless | 79 | 5.9 |
n = 1343 who answered “I have never seen this site” in Table 10.